Nature Reviews Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 16, 2025
Language: Английский
Nature Reviews Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 16, 2025
Language: Английский
Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)
Published: June 19, 2023
T cells are crucial for immune functions to maintain health and prevent disease. cell development occurs in a stepwise process the thymus mainly generates CD4
Language: Английский
Citations
359Cell, Journal Year: 2021, Volume and Issue: 184(25), P. 6101 - 6118.e13
Published: Nov. 30, 2021
Language: Английский
Citations
311Cell, Journal Year: 2022, Volume and Issue: 185(22), P. 4049 - 4066.e25
Published: Oct. 1, 2022
Language: Английский
Citations
248Nature reviews. Cancer, Journal Year: 2023, Volume and Issue: 23(5), P. 295 - 316
Published: April 12, 2023
Language: Английский
Citations
240Cell, Journal Year: 2023, Volume and Issue: 186(6), P. 1127 - 1143.e18
Published: March 1, 2023
CD8
Language: Английский
Citations
218Immunity, Journal Year: 2022, Volume and Issue: 56(1), P. 107 - 124.e5
Published: Dec. 28, 2022
Language: Английский
Citations
193Nature Cancer, Journal Year: 2022, Volume and Issue: 3(9), P. 1123 - 1136
Published: Sept. 22, 2022
Language: Английский
Citations
172Immunity, Journal Year: 2023, Volume and Issue: 56(10), P. 2231 - 2253
Published: Oct. 1, 2023
Language: Английский
Citations
161Nature Immunology, Journal Year: 2022, Volume and Issue: 23(6), P. 836 - 847
Published: May 27, 2022
Language: Английский
Citations
121Immune Network, Journal Year: 2022, Volume and Issue: 22(1)
Published: Jan. 1, 2022
Targeting immune evasion via checkpoint pathways has changed the treatment paradigm in cancer. Since CTLA-4 antibody was first approved 2011 for of metastatic melanoma, eight inhibitors (ICIs) centered on PD-1 pathway blockade are and currently administered to treat 18 different types cancers. The part review focuses history discovery preclinical experiments that demonstrated possibility anti-CTLA-4 anti-PD-1 as anti-cancer therapeutics. approval process clinical trials utility ICIs described, specifically focusing non-small cell lung cancer (NSCLC), which immunotherapies most actively applied. Additionally, this covers combination therapy novel under investigation NSCLC. Although now key pivotal option settings, they show inconsistent therapeutic efficacy limited responsiveness. Thus, newly proposed action mechanism overcome limitations a near future also discussed.
Language: Английский
Citations
115